Eledon Pharmaceuticals (ELDN) 10-Q2022 Q1 Quarterly report

Filed: 12 May 22, 5:01pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: ATM, attendance, Australia, baby, BLA, budesonide, chain, cohort, conflict, deliberate, enhance, escalation, exceed, expansion, facility, filtering, float, heightened, home, hospital, incorrect, IND, instability, installing, invasion, Letter, Malaysia, mask, military, movement, NOL, Objection, Omicron, outbreak, overhead, political, practice, prioritization, protein, quickly, recession, region, regional, Russia, Russian, shelf, shipping, shutting, site, sooner, SPARSENTAN, statement, succeeding, TARPEYO, tegoprubart, tegopurbart, transmission, Ukraine, upheaval, urinary, Zealand

Removed: accelerated, accompanied, accounted, accredited, agent, alerting, allocation, ALSTDI, announced, announcement, anti, applying, ASC, assigned, assumed, ASU, attributed, authoritative, Blvd, book, Certificate, chapter, check, clarified, closing, Codification, combine, combined, combining, Concurrently, constitute, context, Conversely, convert, converted, Cormorant, create, curtailed, dated, deductible, depreciation, Designation, detail, deterioration, determining, distributed, dormant, durable, ELDN, electronically, emerging, endpoint, ENT, exhaustive, expanding, experimental, expressly, facing, faith, FASB, filer, focal, forma, good, hereof, ICT, Identification, iii, illustrate, incorporation, inducement, induction, informational, inhibitor, input, intangible, intent, Interactive, intervention, legacy, lived, LP, MacArthur, mark, Master, merged, Mine, Nasdaq, NDA, nominal, obsolescence, orphan, par, pathology, perception, placement, preceding, precise, pro, project, PRSU, purport, qualify, Qualitative, Quantitative, recapitalization, recreate, registered, registrant, relied, reorganization, replaced, replica, risky, RSU, satisfied, segmental, serviced, settled, settlement, shareholder, shell, shorter, significance, situation, sought, speak, speculative, statistical, substantive, sufficiency, Suite, surviving, Topic, transaction, transferred, transpire, travel, Unregistered, update, utility, valuation, warrant

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ELDN transcripts

ELDN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Eledon Pharmaceuticals, Inc. (the “Company”) for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, David-Alexandre C. Gros, M.D., Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of
1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 12, 2022

By:

/s/ David-Alexandre C. Gros, M.D.

David-Alexandre C. Gros, M.D.

Chief Executive Officer

(Principal Executive Officer)